Izalontamab brengitecan
- Generic Name
- Izalontamab brengitecan
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06978114
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Phase 2
Not yet recruiting
- Conditions
- Renal Cancer
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06962787
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC
Phase 2
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 40
- Registration Number
- NCT06951464
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
Phase 3
Recruiting
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 674
- Registration Number
- NCT06857175
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 696
- Registration Number
- NCT06838273
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06787664
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT06618287
- Locations
- 🇺🇸
Local Institution - 0066, Birmingham, Alabama, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇨🇦The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 714
- Registration Number
- NCT06500026
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06498986
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase 2
Recruiting
- Conditions
- Nasopharyngeal CarcinomaNon-small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 332
- Registration Number
- NCT06475300
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath